Targeting the Akt/mTOR Pathway in Brca1-Deficient Cancers

Oncogene - United Kingdom
doi 10.1038/onc.2010.603
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Targeting the PI3K/AKT/MTOR Pathway in KSHV-associated Cancers

Infectious Agents and Cancer
Cancer ResearchEpidemiologyOncologyInfectious Diseases
2009English

Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway

Surgical Oncology Clinics of North America
SurgeryOncology
2013English

Targeting the PI3K/Akt/mTOR Signalling Pathway in Cystic Fibrosis

Scientific Reports
Multidisciplinary
2017English

Pre-Clinical Activity of Targeting the PI3K/Akt/mTOR Pathway in Burkitt Lymphoma

Oncotarget
Oncology
2018English

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

Clinical Cancer Drugs
Cancer ResearchToxicologyOncologyPharmaceuticsPharmacology
2016English

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

miR‑122 and miR‑199 Synergistically Promote Autophagy In�oral Lichen Planus by Targeting the Akt/mTOR Pathway

International Journal of Molecular Medicine
MedicineGenetics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy